MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Issue-specific ESG scores. These are ESG scores that measure the performance of companies and funds based on a single issue.
Medincell’s ESG disclosure is classified at a very high transparency level Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results